lipids, one or more stabilizing agents, one or more neutralizing agents, or any combination thereof. A therapeutic compound may have an anti-inflammatory activity.

**[08a]** In one aspect, there is provided a solid solution pharmaceutical composition comprising:

a) one or more non-steroidal anti-inflammatory drugs (NSAIDs) in an amount of about 20% to about 40% by weight of the pharmaceutical composition;
b) one or more pharmaceutically-acceptable hard fats in an amount of at least 30% by weight of the pharmaceutical composition; and
c) one or more pharmaceutically-acceptable monoglycerides or acetylated monoglycerides that is liquid at room temperature in an amount of less than 30% by weight of the pharmaceutical composition,

wherein the solid solution pharmaceutical composition is formulated to be a solid at a temperature of about 15°C or lower.

**[08b]** In one aspect, there is provided use of a pharmaceutical composition as defined herein in the manufacture of a medicament for the treatment of a chronic inflammation.

**[08c]** In one aspect, there is provided of a pharmaceutical composition as defined herein for the treatment of a chronic inflammation.

**[09]** Other aspects of the present specification disclose, in part, a method of preparing a solid solution pharmaceutical composition disclosed herein. A method disclosed herein comprises the steps of a) contacting a therapeutic compound disclosed herein with one or more room temperature liquid lipids under conditions which allow the therapeutic compound to dissolve in the lipids; and b) contacting the compound/lipid solution with one or more room temperature solid lipids under conditions which allow the formation of a solid solution composition. In aspects of this method, heat is applied to dissolve the therapeutic compound into the one or more room temperature liquid lipids to create a solution. In other aspects of this method, step (a) comprises contacting a therapeutic compound disclosed herein with one or more room temperature liquid lipids and/or one or more stabilizing agents, and/or one or more neutralizing agents under conditions which allow the therapeutic compound to dissolve in the lipids.

**[010]** Other aspects of the present specification disclose a method of treating an individual with a chronic inflammation, the method comprising the step of administering to the individual in need thereof a solid solution pharmaceutical composition disclosed herein, wherein administration results in a reduction in a symptom associated with the chronic inflammation, thereby treating the individual.

**[011]** Other aspects of the present specification disclose a use of a solid solution pharmaceutical composition disclosed herein in the manufacture of a medicament for the treatment of a chronic inflammation.

**[012]** Other aspects of the present specification disclose a solid solution pharmaceutical composition disclosed herein for use in the treatment of a chronic inflammation.

**[013]** Other aspects of the present specification disclose a use of a solid solution pharmaceutical composition disclosed herein for the treatment of a chronic inflammation.

## BREIF DESCRIPTION OF THE DRAWINGS

**[014]** **FIG. 1** shows a differential scanning calorimetry (DSC) graph of solid solution compositions disclosed herein comprising ibuprofen. **FIG. 1A** is a DSC graph of ibuprofen alone exhibiting a melting point range of 75°C to 78°C; **FIG. 1B** is a DSC graph of GELUCIE® 43/01 alone exhibiting a melting point range of 41°C to 45°C; **FIG. 1C** is a DSC graph of a vehicle comprising GELUCIE® 43/01, MAISINE® 35-1, and PEG 400 exhibiting a melting point ranges of 32°C to 38°C and 41°C to 45°C; **FIG. 1D** is a DSC graph of Ibuprofen composition LA 35-1 exhibiting a melting point range of 32°C to 44°C; **FIG. 1E** is a DSC graph of Ibuprofen composition LA 35-2 exhibiting a melting point range of 32°C to 43°C; **FIG. 1F** is a DSC graph of Ibuprofen composition LA 35-1 exhibiting a melting point range of 32°C to 42°C; **FIG. 1G** is a DSC graph of Ibuprofen composition LA 35-1 exhibiting a melting point range of 32°C to 38°C; **FIG. 1H** is a DSC graph of Ibuprofen composition LA 35-1 exhibiting a melting point range of 32°C to 42°C.

lipids, one or more stabilizing agents, one or more neutralizing agents, or any combination thereof. A therapeutic compound may have an anti-inflammatory activity.

**[08a]** In one aspect, there is provided an oral solid solution pharmaceutical composition comprising:

a) one or more non-steroidal anti-inflammatory drugs (NSAIDs) in an amount of about 20% to about 40% by weight of the pharmaceutical composition;

b) one or more pharmaceutically-acceptable hard fats, wherein the one or more hard fats include one or more triglycerides in an amount of at least 30% by weight of the pharmaceutical composition, the one or more triglycerides comprising a triglyceride with one saturated or unsaturated fatty acid having a carbon length of C12-C24, two saturated or unsaturated fatty acids each having a carbon length of C12-C24, or three saturated or unsaturated fatty acids each having a carbon length of C12-C24; and

c) one or more pharmaceutically- acceptable liquid fat in an amount of less than 30% by weight of the pharmaceutical composition and comprising a monoglyceride or acetylated monoglyceride and a diglyceride, wherein the monoglyceride or the acetylated monoglyceride has a fatty acid of at least 12 carbons,

wherein the solid solution pharmaceutical composition does not comprise a surfactant; and

wherein the solid solution pharmaceutical composition is formulated to be a solid at a temperature of about 15°C or lower and has a melting point of 30°C or higher.

**[08b]** In one aspect, there is provided use of a pharmaceutical composition as defined herein in the manufacture of a medicament for the treatment of a chronic inflammation.

**[08c]** In one aspect, there is provided of a pharmaceutical composition as defined herein for the treatment of a chronic inflammation.

**[09]** Other aspects of the present specification disclose, in part, a method of preparing a solid solution pharmaceutical composition disclosed herein. A method disclosed herein comprises the steps of a) contacting a therapeutic compound disclosed herein with one or more room temperature liquid lipids under conditions which allow the therapeutic compound to dissolve in the lipids; and b) contacting the compound/lipid solution with one or more room temperature solid lipids under conditions which allow the formation of a solid solution composition. In aspects of this method, heat is applied to dissolve the therapeutic compound into the one or more room temperature liquid lipids to create a solution. In other aspects of this method, step (a) comprises contacting a therapeutic compound disclosed herein with one or more room temperature liquid lipids and/or one or more stabilizing agents, and/or one or more neutralizing agents under conditions which allow the therapeutic compound to dissolve in the lipids.

**[010]** Other aspects of the present specification disclose a method of treating an individual with a chronic inflammation, the method comprising the step of administering to the individual in need thereof a solid solution pharmaceutical composition disclosed herein, wherein administration results in a reduction in a symptom associated with the chronic inflammation, thereby treating the individual.

**[011]** Other aspects of the present specification disclose a use of a solid solution pharmaceutical composition disclosed herein in the manufacture of a medicament for the treatment of a chronic inflammation.

**[012]** Other aspects of the present specification disclose a solid solution pharmaceutical composition disclosed herein for use in the treatment of a chronic inflammation.

**[013]** Other aspects of the present specification disclose a use of a solid solution pharmaceutical composition disclosed herein for the treatment of a chronic inflammation.

## BREIF DESCRIPTION OF THE DRAWINGS

**[014]** **FIG. 1** shows a differential scanning calorimetry (DSC) graph of solid solution compositions disclosed herein comprising ibuprofen. **FIG. 1A** is a DSC graph of ibuprofen alone exhibiting a melting point range of 75°C to 78°C; **FIG. 1B** is a DSC graph of GELUCIE® 43/01 alone exhibiting a melting point range of 41°C to 45°C; **FIG. 1C** is a DSC graph of a vehicle comprising GELUCIE® 43/01, MAISINE® 35-1, and PEG 400 exhibiting a melting point ranges of 32°C to 38°C and 41°C to 45°C; **FIG. 1D** is a DSC graph of Ibuprofen composition LA 35-1 exhibiting a melting point range of 32°C to 44°C; **FIG. 1E** is a DSC graph of Ibuprofen composition LA 35-2 exhibiting a melting point range of 32°C to 43°C; **FIG. 1F** is a DSC graph of Ibuprofen composition LA 35-1 exhibiting a melting point range of 32°C to 42°C; **FIG. 1G** is a DSC graph of Ibuprofen composition LA 35-1 exhibiting a melting point range of 32°C to 38°C; **FIG. 1H** is a DSC graph of Ibuprofen composition LA 35-1 exhibiting a melting point range of 32°C to 42°C.

## CLAIMS

1. A solid solution pharmaceutical composition comprising:

   a) one or more non-steroidal anti-inflammatory drugs (NSAIDs) in an amount of about 20% to about 40% by weight of the pharmaceutical composition;

   b) one or more pharmaceutically-acceptable hard fats in an amount of at least 30% by weight of the pharmaceutical composition; and

   c) one or more pharmaceutically-acceptable monoglycerides or acetylated monoglycerides that is liquid at room temperature in an amount of less than 30% by weight of the pharmaceutical composition,

   wherein the solid solution pharmaceutical composition is formulated to be a solid at a temperature of about 15°C or lower.

2. The solid solution pharmaceutical composition according to Claim 1, wherein the amount of the one or more NSAIDs is about 25% to about 35% by weight of the pharmaceutical composition.

3. The pharmaceutical composition according to Claim 1 or Claim 2, wherein the one or more NSAIDs comprises a non-selective cyclo-oxygenase inhibitor, a selective cyclooxygenase 1 inhibitor, a selective cyclooxygenase 2 inhibitor or any combination thereof.

4. The pharmaceutical composition according to Claim 3, wherein the one or more NSAIDs comprises a pharmaceutically-acceptable form of a salicylate derivative NSAID, a pharmaceutically-acceptable form of a p-amino phenol derivative NSAID, a pharmaceutically-acceptable form of a propionic acid derivative NSAID, a pharmaceutically-acceptable form of an acetic acid derivative NSAID, a pharmaceutically-acceptable form of an enolic acid derivative NSAID, a pharmaceutically-acceptable form of a fenamic acid derivative NSAID, an ester of the NSAID, or any combination thereof.

5. The pharmaceutical composition according to Claim 4, wherein the propionic acid derivative NSAID comprises a pharmaceutically-acceptable form of an Alminoprofen, a pharmaceutically-acceptable form of a Benoxaprofen, a pharmaceutically-acceptable form of a Dexketoprofen, a pharmaceutically-acceptable form of a Fenoprofen, a pharmaceutically-acceptable form of a Flurbiprofen, a pharmaceutically-acceptable form of an Ibuprofen, a pharmaceutically-acceptable form of an Indoprofen, a pharmaceutically-acceptable form of a Ketoprofen, a pharmaceutically-acceptable form of a Loxoprofen, a pharmaceutically-acceptable form of a Naproxen, a pharmaceutically-acceptable form of an Oxaprozin, a pharmaceutically-acceptable form of a Pranoprofen, or a pharmaceutically-acceptable form of a Suprofen.

6. The pharmaceutical composition according to Claim 5, wherein the propionic acid derivative NSAID is a pharmaceutically-acceptable form of an Ibuprofen.

7. The solid solution pharmaceutical composition according to any one of Claims 1-6, wherein the amount of the one or more pharmaceutically-acceptable hard fats is about 35% to about 45% by weight of the pharmaceutical composition.

8. The solid solution pharmaceutical composition according to any one of Claims 1-7, wherein the one or more pharmaceutically-acceptable hard fats have a melting point of about 40°C to about 50°C.

9. The solid solution pharmaceutical composition according to Claim 8, wherein the one or more pharmaceutically-acceptable hard fats comprise one or more glycerolipids.

10. The solid solution pharmaceutical composition according to Claim 9, wherein the one or more glycerolipids comprise a triglyceride with one saturated or unsaturated fatty acid having a carbon

length of $C_{12}$-$C_{24}$, two saturated or unsaturated fatty acids each having a carbon length of $C_{12}$-$C_{24}$, or three saturated or unsaturated fatty acids each having a carbon length of $C_{12}$-$C_{24}$.

11. The solid solution pharmaceutical composition according to Claim 9 or Claim 10, wherein the one or more glycerolipids comprise a mixture of saturated $C_{10}$-$C_{18}$ triglycerides having a melting point range of about 41°C to 45°C.

12. The solid solution pharmaceutical composition according to any one of Claims 1-11, wherein the amount of the one or more pharmaceutically-acceptable monoglycerides or acetylated monoglycerides is about 8% to about 30% by weight of the pharmaceutical composition.

13. The solid solution pharmaceutical composition according to any one of Claims 1-12, wherein the amount of the one or more pharmaceutically-acceptable monoglycerides or an acetylated monoglycerides is less than 25% by weight of the pharmaceutical composition.

14. The solid solution pharmaceutical composition according to any one of Claims 1-13, wherein the one or more pharmaceutically-acceptable monoglycerides or an acetylated monoglycerides comprise glycerol monomyristoleate, glycerol monopalmitoleate, glycerol monosapienate, glycerol monooleate, glycerol monoelaidate, glycerol monovaccenate, glycerol monolinoleate, glycerol monolinoelaidate, glycerol monolinolenate, glycerol monostearidonate, glycerol monoeicosenoate, glycerol monomeadate, glycerol monoarachidonate, glycerol monoeicosapentaenoate, glycerol monoerucate, glycerol monodocosahexaenoate, or glycerol mononervonate.

15. The solid solution pharmaceutical composition according to Claims 14, wherein the one or more pharmaceutically-acceptable monoglycerides or acetylated monoglycerides comprise glycerol monolinoleate.

16. The solid solution pharmaceutical composition according to any one of Claims 1-15, wherein the solid solution pharmaceutical composition further comprises one or more stabilizing agents and/or one or more neutralizing agents.

17. The solid solution pharmaceutical composition according to Claim 16, wherein the one or more stabilizing agents comprises about 1% to about 5% by weight of the pharmaceutical composition.

18. The solid solution pharmaceutical composition according to Claim 17, wherein the one or more stabilizing agents comprises a liquid glycol polymer, a monohydric alcohol, isosorbide dimethyl ether, and diethylene glycol monoethyl ether (2-(2-ethoxyethoxy)ethanol).

19. The solid solution pharmaceutical composition according to Claim 18, wherein the liquid glycol polymer is a liquid polyethylene glycol (PEG) polymer and/or a liquid polypropylene glycol (PPG) polymer.

20. The solid solution pharmaceutical composition according to Claim 19, wherein the liquid glycol polymer in an amount of about 5% to about 15% by weight of the pharmaceutical composition.

21. The solid solution pharmaceutical composition according to Claim 20, wherein the liquid glycol polymer in an amount of about 9% to about 12% by weight of the pharmaceutical composition

22. The pharmaceutical composition according to any one of Claims 19-21, wherein the PEG polymer is no more than about 1,000 g/mol.

23. The pharmaceutical composition according to Claim 22, wherein the PEG polymer comprises a PEG 100, a PEG 200, a PEG 300, a PEG 400, a PEG 500, a PEG 600, a PEG 700, a PEG 800, a PEG 900, a PEG 1000, or any combination thereof.

24. The solid solution pharmaceutical composition according to Claim 16, wherein the one or more neutralizing agents comprises about 5% to 55% by weight of the pharmaceutical composition.

25. The solid solution pharmaceutical composition according to Claim 24, wherein the one or more neutralizing agents comprises one or more fatty acids, sodium acetate, or triethanolamine.

26. The solid solution pharmaceutical composition according to Claim 25, wherein the one or more fatty acids comprises a $C_{16}$-$C_{18}$ fatty acid.

27. Use of a pharmaceutical composition as defined in any one of Claims 1-26 in the manufacture of a medicament for the treatment of a chronic inflammation.

28. Use of a pharmaceutical composition as defined in any one of Claims 1-26 for the treatment of a chronic inflammation.

29. The use according to Claim 27 or Claim 28, wherein the chronic inflammation is associated with acne, acid reflux/heartburn, age related macular degeneration (AMD), allergy, allergic rhinitis, Alzheimer's disease, amyotrophic lateral sclerosis, anemia, appendicitis, arteritis, arthritis, asthma. atherosclerosis, autoimmune disorders, balanitis, blepharitis, bronchiolitis, bronchitis, a bullous pemphigoid, burn, bursitis, cancer, cardiac arrest, carditis, celiac disease, cellulitis, cervicitis, cholangitis, cholecystitis, chorioamnionitis, chronic obstructive pulmonary disease (COPD), cirrhosis, colitis, congestive heart failure, conjunctivitis, cyclophosphamide-induced cystitis, cystic fibrosis, cystitis, common cold, dacryoadenitis, dementia, dermatitis, dermatomyositis, diabetes, diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic ulcer, digestive system disease, eczema, emphysema, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibromyalgia, fibrosis, fibrositis, gastritis, gastroenteritis, gingivitis, glomerulonephritis, glossitis, heart disease, heart valve dysfunction, hepatitis, hidradenitis suppurativa, Huntington's disease, hyperlipidemic pancreatitis, hypertension, ileitis, infection, inflammatory bowel disease, inflammatory cardiomegaly, inflammatory neuropathy, insulin resistance, interstitial cystitis, interstitial nephritis, iritis, ischemia, ischemic heart disease, keratitis, keratoconjunctivitis, laryngitis, lupus nephritis, mastitis, mastoiditis, meningitis, metabolic syndrome (syndrome X), a migraine, multiple sclerosis, myelitis, myocarditis, myositis, nephritis, non-alcoholic steatohepatitis, obesity, omphalitis, oophoritis, orchitis, osteochondritis, osteopenia, osteomyelitis, osteoporosis, osteitis, otitis, pancreatitis, Parkinson's disease, parotitis, pelvic inflammatory disease, pemphigus vularis, pericarditis, peritonitis, pharyngitis, phlebitis, pleuritis, pneumonitis, polycystic nephritis, proctitis, prostatitis, psoriasis, pulpitis, pyelonephritis, pylephlebitis, renal failure, reperfusion injury, retinitis, rheumatic fever, rhinitis, salpingitis, sarcoidosis, sialadenitis, sinusitis, spastic colon, stenosis, stomatitis, stroke, surgical complication, synovitis, tendonitis, tendinosis, tenosynovitis, thrombophlebitis, tonsillitis, trauma, traumatic brain injury, transplant rejection, trigonitis, tuberculosis, tumor, urethritis, ursitis, uveitis, vaginitis, vasculitis, or vulvitis.

30. The use according to Claim 27 or Claim 28, wherein the chronic inflammation is a tissue inflammation or a systemic inflammation.

31. The use according to Claim 27 or Claim 28, wherein the chronic inflammation is an auto-immune disease or a non-autoimmune disease.

32 The use according to Claim 27 or Claim 28, wherein the chronic inflammation is associated with an arthritis, a myopathy, a vasculitis, a skin disorder, a gastrointestinal disorder, a cardiovascular disease, a cancer, a pharmacologically-induced inflammation, an infection, a tissue or organ injury, a transplant rejection, a graft-versus-host disease, a Th1-mediated inflammatory disease, a chronic neurogenic inflammation.

## CLAIMS

1. An oral solid solution pharmaceutical composition comprising:

   a) one or more non-steroidal anti-inflammatory drugs (NSAIDs) in an amount of about 20% to about 40% by weight of the pharmaceutical composition;

   b) one or more pharmaceutically-acceptable hard fats, wherein the one or more hard fats include one or more triglycerides in an amount of at least 30% by weight of the pharmaceutical composition, the one or more triglycerides comprising a triglyceride with one saturated or unsaturated fatty acid having a carbon length of $C_{12}$-$C_{24}$, two saturated or unsaturated fatty acids each having a carbon length of $C_{12}$-$C_{24}$, or three saturated or unsaturated fatty acids each having a carbon length of $C_{12}$-$C_{24}$; and

   c) one or more pharmaceutically- acceptable liquid fat in an amount of less than 30% by weight of the pharmaceutical composition and comprising a monoglyceride or acetylated monoglyceride and a diglyceride, wherein the monoglyceride or the acetylated monoglyceride has a fatty acid of at least 12 carbons,

   wherein the solid solution pharmaceutical composition does not comprise a surfactant; and

   wherein the solid solution pharmaceutical composition is formulated to be a solid at a temperature of about 15°C or lower and has a melting point of 30°C or higher.

2. The solid solution pharmaceutical composition according to Claim 1, wherein the amount of the one or more NSAIDs is about 25% to about 35% by weight of the pharmaceutical composition.

3. The pharmaceutical composition according to Claim 1 or Claim 2, wherein the one or more NSAIDs comprises a non-selective cyclo-oxygenase inhibitor, a selective cyclooxygenase 1 inhibitor, a selective cyclooxygenase 2 inhibitor or any combination thereof.

4. The pharmaceutical composition according to Claim 3, wherein the one or more NSAIDs comprises a pharmaceutically-acceptable form of a salicylate derivative NSAID, a pharmaceutically-acceptable form of a p-amino phenol derivative NSAID, a pharmaceutically-acceptable form of a propionic acid derivative NSAID, a pharmaceutically-acceptable form of an acetic acid derivative NSAID, a pharmaceutically-acceptable form of an enolic acid derivative NSAID, a pharmaceutically-acceptable form of a fenamic acid derivative NSAID, an ester of the NSAID, or any combination thereof.

5. The pharmaceutical composition according to Claim 4, wherein the propionic acid derivative NSAID comprises a pharmaceutically-acceptable form of an Alminoprofen, a pharmaceutically-acceptable form of a Benoxaprofen, a pharmaceutically-acceptable form of a Dexketoprofen, a pharmaceutically-acceptable form of a Fenoprofen, a pharmaceutically-acceptable form of a Flurbiprofen, a pharmaceutically-acceptable form of an Ibuprofen, a pharmaceutically-acceptable form of an Indoprofen, a pharmaceutically-acceptable form of a Ketoprofen, a pharmaceutically-acceptable form of a Loxoprofen, a pharmaceutically-acceptable form of a Naproxen, a pharmaceutically-acceptable form of an Oxaprozin, a pharmaceutically-acceptable form of a Pranoprofen, or a pharmaceutically-acceptable form of a Suprofen.

6. The pharmaceutical composition according to Claim 5, wherein the propionic acid derivative NSAID is a pharmaceutically-acceptable form of an Ibuprofen.

7. The solid solution pharmaceutical composition according to any one of Claims 1-6, wherein the amount of the one or more pharmaceutically-acceptable hard fats is about 35% to about 45% by weight of the pharmaceutical composition.

8. The solid solution pharmaceutical composition according to any one of Claims 1-7, wherein the one or more pharmaceutically-acceptable hard fats have a melting point of about 40°C to about 50°C.

9. The solid solution pharmaceutical composition according to any one of Claims 1-8, wherein the one or more triglycerides comprise a mixture of saturated $C_{10}$-$C_{18}$ triglycerides having a melting point range of about 41°C to 45°C.

10. The solid solution pharmaceutical composition according to Claim 9, wherein the one or more triglycerides comprise a mixture of saturated $C_{10}$-$C_{18}$ triglycerides having a melting point range of about 43°C.

11. The solid solution composition according to any one of Claims 1-10, wherein the one or more NSAIDs have a logP of about 2.2 to about 3.0.

12. The solid solution pharmaceutical composition according to any one of Claims 1-11, wherein the amount of the one or more pharmaceutically-acceptable monoglycerides or acetylated monoglycerides is about 8% to about 30% by weight of the pharmaceutical composition.

13. The solid solution pharmaceutical composition according to any one of Claims 1-12, wherein the amount of the one or more pharmaceutically-acceptable monoglycerides or an acetylated monoglycerides is less than 25% by weight of the pharmaceutical composition.

14. The solid solution pharmaceutical composition according to any one of Claims 1-13, wherein the one or more pharmaceutically-acceptable monoglycerides or an acetylated monoglycerides comprise glycerol monomyristoleate, glycerol monopalmitoleate, glycerol monosapienate, glycerol monooleate, glycerol monoelaidate, glycerol monovaccenate, glycerol monolinoleate, glycerol monolinoelaidate, glycerol monolinolenate, glycerol monostearidonate, glycerol monoeicosenoate, glycerol monomeadate, glycerol monoarachidonate, glycerol monoeicosapentaenoate, glycerol monoerucate, glycerol monodocosahexaenoate, or glycerol mononervonate.

15. The solid solution pharmaceutical composition according to Claims 14, wherein the one or more pharmaceutically-acceptable monoglycerides or acetylated monoglycerides comprise glycerol monolinoleate.

16. The solid solution pharmaceutical composition according to any one of Claims 1-15, wherein the solid solution pharmaceutical composition further comprises one or more stabilizing agents and/or one or more neutralizing agents.

17. The solid solution pharmaceutical composition according to Claim 16, wherein the one or more stabilizing agents comprises about 1% to about 5% by weight of the pharmaceutical composition.

18. The solid solution pharmaceutical composition according to Claim 17, wherein the one or more stabilizing agents comprises a liquid glycol polymer, a monohydric alcohol,

isosorbide dimethyl ether, and diethylene glycol monoethyl ether (2-(2-ethoxyethoxy)ethanol).

19. The solid solution pharmaceutical composition according to Claim 18, wherein the liquid glycol polymer is a liquid polyethylene glycol (PEG) polymer and/or a liquid polypropylene glycol (PPG) polymer.

20. The solid solution pharmaceutical composition according to Claim 19, wherein the liquid glycol polymer in an amount of about 5% to about 15% by weight of the pharmaceutical composition.

21. The solid solution pharmaceutical composition according to Claim 20, wherein the liquid glycol polymer in an amount of about 9% to about 12% by weight of the pharmaceutical composition

22. The pharmaceutical composition according to any one of Claims 19-21, wherein the PEG polymer is no more than about 1,000 g/mol.

23. The pharmaceutical composition according to Claim 22, wherein the PEG polymer comprises a PEG 100, a PEG 200, a PEG 300, a PEG 400, a PEG 500, a PEG 600, a PEG 700, a PEG 800, a PEG 900, a PEG 1000, or any combination thereof.

24. The solid solution pharmaceutical composition according to Claim 16, wherein the one or more neutralizing agents comprises about 5% to 55% by weight of the pharmaceutical composition.

25. The solid solution pharmaceutical composition according to Claim 24, wherein the one or more neutralizing agents comprises one or more fatty acids, sodium acetate, or triethanolamine.

26. The solid solution pharmaceutical composition according to Claim 25, wherein the one or more fatty acids comprises a $C_{16}$-$C_{18}$ fatty acid.

27. Use of an oral solid solution pharmaceutical composition as defined in any one of Claims 1-26 in the manufacture of a medicament for the treatment of a chronic inflammation.

28. The use according to Claim 27, wherein the chronic inflammation is associated with acne, acid reflux/heartburn, age related macular degeneration (AMD), allergy, allergic rhinitis, Alzheimer's disease, amyotrophic lateral sclerosis, anemia, appendicitis, arteritis, arthritis, asthma. atherosclerosis, autoimmune disorders, balanitis, blepharitis, bronchiolitis, bronchitis, a bullous pemphigoid, burn, bursitis, cancer, cardiac arrest, carditis, celiac disease, cellulitis, cervicitis, cholangitis, cholecystitis, chorioamnionitis, chronic obstructive pulmonary disease (COPD), cirrhosis, colitis, congestive heart failure, conjunctivitis, cyclophosphamide-induced cystitis, cystic fibrosis, cystitis, common cold, dacryoadenitis, dementia, dermatitis, dermatomyositis, diabetes, diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic ulcer, digestive system disease, eczema, emphysema, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibromyalgia, fibrosis, fibrositis, gastritis, gastroenteritis, gingivitis, glomerulonephritis, glossitis, heart disease, heart valve dysfunction, hepatitis, hidradenitis suppurativa, Huntington's disease, hyperlipidemic pancreatitis, hypertension, ileitis, infection, inflammatory bowel disease, inflammatory cardiomegaly, inflammatory neuropathy, insulin resistance, interstitial cystitis, interstitial nephritis, iritis, ischemia, ischemic heart disease, keratitis, keratoconjunctivitis, laryngitis, lupus nephritis, mastitis, mastoiditis, meningitis, metabolic syndrome (syndrome X), a migraine, multiple sclerosis, myelitis, myocarditis, myositis, nephritis, non-alcoholic

steatohepatitis, obesity, omphalitis, oophoritis, orchitis, osteochondritis, osteopenia, osteomyelitis, osteoporosis, osteitis, otitis, pancreatitis, Parkinson's disease, parotitis, pelvic inflammatory disease, pemphigus vularis, pericarditis, peritonitis, pharyngitis, phlebitis, pleuritis, pneumonitis, polycystic nephritis, proctitis, prostatitis, psoriasis, pulpitis, pyelonephritis, pylephlebitis, renal failure, reperfusion injury, retinitis, rheumatic fever, rhinitis, salpingitis, sarcoidosis, sialadenitis, sinusitis, spastic colon, stenosis, stomatitis, stroke, surgical complication, synovitis, tendonitis, tendinosis, tenosynovitis, thrombophlebitis, tonsillitis, trauma, traumatic brain injury, transplant rejection, trigonitis, tuberculosis, tumor, urethritis, ursitis, uveitis, vaginitis, vasculitis, or vulvitis.

29. The use according to Claim 27, wherein the chronic inflammation is a tissue inflammation or a systemic inflammation.

30. The use according to Claim 27, wherein the chronic inflammation is an auto-immune disease or a non-autoimmune disease.

31 The use according to Claim 27, wherein the chronic inflammation is associated with an arthritis, a myopathy, a vasculitis, a skin disorder, a gastrointestinal disorder, a cardiovascular disease, a cancer, a pharmacologically-induced inflammation, an infection, a tissue or organ injury, a transplant rejection, a graft-versus-host disease, a Th1-mediated inflammatory disease, a chronic neurogenic inflammation.